Matthieu Ternois
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthieu Ternois has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A.A. Abena
Université Marien Ngouabi, Faculté des sciences et de la santé, Brazzaville, République du Congo
1 shared publicationC. Lefevre
CHU Hôpital Jeanne de Flandres, Lille, France
1 shared publicationC. Stukens
CHU Hôpital Jeanne de Flandres, Lille, France
1 shared publicationD. Moukassa
Hôpital Général de Loandjili, Pointe Noire, Republic of Congo
1 shared publication- Didier Hober
Laboratoire de Virologie ULR3610 Univ Lille et CHU de Lille Lille France
1 shared publication E. Bouenizabila
CHU de Brazzaville, Brazzaville, Republic of Congo
1 shared publication
Latest Publications
- 1 October 2018
- Published by Elsevier in Actualites Pharmaceutiques
- Vol. 57 (579) , 22-26
Diabetes and oral health
- 1 October 2018
- Published by Elsevier in Actualites Pharmaceutiques
- Vol. 57 (579) , 22-26
Diabetes and oral health
- 1 September 2017
- Published by Elsevier in La Presse Médicale
- Vol. 46 (9) , 822-830
La bouche : un miroir du diabète
- 1 September 2017
- Published by Elsevier in La Presse Médicale
- Vol. 46 (9) , 822-830
La bouche : un miroir du diabète
- 18 July 2017
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 33 (7)
Marker of coxsackievirus‐B4 infection in saliva of patients with type 1 diabetes
Background: Coxsackieviruses B (CV‐B) are enteroviruses that have been reported to play a role in the pathogenesis of type 1 diabetes. Enteroviral RNA was detected in the gut mucosa of patients. The mucosal immunity is an interconnected network; therefore, the response to enteroviruses possibly present in the gastrointestinal mucosa can be reflected by specific antibodies in the saliva. In the present study, the anti‐CV‐B neutralizing activity of saliva samples from patients with type 1 diabetes was investigated.Methods: Saliva samples were collected from patients and controls of 3 countries, and plasma was obtained from some of them. The anti‐CV‐B activity of clinical samples was determined by neutralization of the cytopathic effect induced by challenging viruses in vitro and expressed as titre value.Results: Overall prevalence and levels of anti‐CV‐B4 activity of saliva were higher in patients (n = 181) than in controls (n = 135; P = .0002; titre values ≥ 16: odds ratio = 4.22 95% CI: 1.90‐9.38 P = .0002). It has been shown that IgA1 played a role in this activity. There was no correlation between the saliva and the plasma anti‐CV‐B4 neutralizing activity. The neutralizing activity of saliva against CV‐B1, CV‐B2, CV‐B3, and CV‐B5 existed rarely, if at all. Increased levels of anti‐CV‐B4 activity were observed all along a 4 year follow‐up period in patients but not in matched controls (P = .01).Conclusion: There is an anti‐CV‐B4 activity in saliva of patients with type 1 diabetes that may be a useful marker to study the role of CV‐B in the pathogenesis of the disease.
- 18 July 2017
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 33 (7)
Marker of coxsackievirus‐B4 infection in saliva of patients with type 1 diabetes
Background: Coxsackieviruses B (CV‐B) are enteroviruses that have been reported to play a role in the pathogenesis of type 1 diabetes. Enteroviral RNA was detected in the gut mucosa of patients. The mucosal immunity is an interconnected network; therefore, the response to enteroviruses possibly present in the gastrointestinal mucosa can be reflected by specific antibodies in the saliva. In the present study, the anti‐CV‐B neutralizing activity of saliva samples from patients with type 1 diabetes was investigated.Methods: Saliva samples were collected from patients and controls of 3 countries, and plasma was obtained from some of them. The anti‐CV‐B activity of clinical samples was determined by neutralization of the cytopathic effect induced by challenging viruses in vitro and expressed as titre value.Results: Overall prevalence and levels of anti‐CV‐B4 activity of saliva were higher in patients (n = 181) than in controls (n = 135; P = .0002; titre values ≥ 16: odds ratio = 4.22 95% CI: 1.90‐9.38 P = .0002). It has been shown that IgA1 played a role in this activity. There was no correlation between the saliva and the plasma anti‐CV‐B4 neutralizing activity. The neutralizing activity of saliva against CV‐B1, CV‐B2, CV‐B3, and CV‐B5 existed rarely, if at all. Increased levels of anti‐CV‐B4 activity were observed all along a 4 year follow‐up period in patients but not in matched controls (P = .01).Conclusion: There is an anti‐CV‐B4 activity in saliva of patients with type 1 diabetes that may be a useful marker to study the role of CV‐B in the pathogenesis of the disease.